Alpha-blocker therapy does not decrease the risk for prostate cancer death, but it is associated with an elevated risk for low-grade prostate cancer. Preclinical studies have suggested that ...

Dr Fred Saad of the University of Montreal discusses the future direction of alpha emitter agents in the treatment of prostate cancer, emphasizing the logical progression of resea ...

Fusion Pharmaceuticals (FUSN) is advancing a candidate which it acquired in February of 2023. It was acquired as an ongoing phase 2 study, known as the TATCIST trial. This is evaluating the use of FPI ...

Vancouver, British Columbia, Canada (Embargoed until 3:15 p.m. PDT, Saturday, June 11, 2022)—A novel targeted radionuclide alpha therapy for metastatic castration-resistant prostate cancer— 225 ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ...

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...

Osaka, Japan - A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray ...

Compounds containing astatine-211 (211At) can be used in targeted radiotherapies for prostate cancer, but deastatination in the body remains a significant hurdle. Now, researchers from Japan have ...

JERUSALEM, June 22, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the first ...

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ...